Business
OTC Markets Group Welcomes New OTCQB Companies – November 1
OTC Markets Group Welcomes New OTCQB Companies – November 1.
About this update from Reflect Scientific, Inc.
[{"type":"text","content":"OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, announced the following companies are approved for trading on the OTCQB Venture Market:ATAC Resources Ltd. (TSX-V: ATC; OTCQB: ATADF) ATAC Resources Ltd. is a well-financed mineral exploration company focused on exploring for gold and copper in Yukon and Nevada. Ongoing work includes testing a new copper porphyry target at the Connaught Property in Yukon, and drilling a high-grade epithermal gold system at the East Goldfield Property in Nevada. Previous work in Yukon at the company's 100%-owned Rackla Gold Project has resulted in delineation of 1,685,000 ounces of gold at 4.23 g/t (in 12.4 Mt) at the Osiris Deposit and a positive Preliminary Economic Assessment for the Tiger Gold Deposit (PEA Pre-Tax NPV of $118.2M and IRR of 54.5%).Battery Mineral Resources Corp. (TSX-V: BMR; OTCQB: BTRMF) Battery Mineral Resources goal is to become a leading low-cost producer of high quality, ethically sourced battery metals from high-grade, low impact mines in stable jurisdictions that are close to major consumer industries and a number of end users and market intermediaries.Eden Research Plc (LSE: EDEN; OTCQB: EDNSF) Development and supply of sustainable biopesticides and plastic-free formulation technology for use in global crop protection, animal health and consumer products industries.FPX Nickel Corp. (TSX-V: FPX; OTCQB: FPOCF) FPX Nickel is a Vancouver-based junior nickel mining company developing the large-scale Decar Nickel District in central British Columbia.Hemostemix Inc. (TSX-V: HEM; OTCQB: HMTXF) Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.JUST KITCHEN HLDGS CORP. (TSX-V: JK; OTCQB: JKHCF) JustKitchen is primarily an operator of ghost kitchens specializing in the development and ...